Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Frank Buck who wrote (672)	12/14/1997 2:37:00 PM
From: Frank Buck	Read Replies (2) \| Respond to of 1894

To All, Here is a paraphrase from the December issue of Bloomberg Personal. It suggests that Price-To- Sales ratios are "better" than market value, book-value-to-market-value and debt to equity in determining low priced value stock appreciation. In a twelve year study period the P/S was concluded to be the only variable that significantly helped explain stock returns in a specific model. Another researcher/author found P/S to be the "best individual ratio" he followed. Low priced P/S are considered a mark of the "unpopular" underfollowed stocks that when realized consistently outperform many other benchmarks of its kind. An example of rotating the 50 "lowest P/S stocks" for a 43 year period turned a $10,000 investment into $5,932,737. If the 50 lowest P/E stocks were used the same $10,000 would have grown into $1,230,992 or the Book/Value Ratio model indicates the $10 K to have sprouted to $3,591,446. Ticker Price/Sales Ratio ACMI - 2.4 ACYT - 41.9 CVSN - N/S CYTC - 22.3 NPTH - 22.9 NSIX - 12.2 Frank